712 North Inc. Expands IP Portfolio with USPTO Patent for Treating Mitochondrial Diseases

February 2, 2021 — 712 North Inc., a pre-clinical pharmaceutical company specializing in mitochondrial medicine, announced today that the United States Patent and Trademark Office (USPTO) has granted a new patent entitled “Methods for treating diseases related to mitochondrial stress.”

The patent covers therapeutic methods aimed at managing the cellular stress responses that lead to mitochondrial breakdown. The grant of this patent reinforces 712 North’s commitment to building a proprietary platform focused on mitochondrial health and cellular resilience.

"This patent is an important addition to our intellectual property,” said Dr. Marcel V. Alavi, CEO of 712 North, “supporting our ongoing development of novel treatments that maintain mitochondrial homeostasis in the face of disease-related stress challenges."

712 North develops personalized mitochondrial medicines for patients with Alzheimer’s and other age-related diseases.

For more information, please visit www.712north.com.